Year All 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2015 2014 Sep 02, 2026 CG Oncology to Present at Upcoming Investor Conferences in September Aug 06, 2026 CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates Jul 27, 2026 CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology May 28, 2026 CG Oncology to Present at Upcoming Investor Conferences in June May 19, 2026 SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award May 15, 2026 CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients May 11, 2026 CG Oncology’s Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC May 08, 2026 CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates May 05, 2026 CG Oncology to Present at Upcoming Investor Conferences in May Feb 27, 2026 CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates
Jul 27, 2026 CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology
May 19, 2026 SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
May 15, 2026 CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients
May 11, 2026 CG Oncology’s Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC